Overview
Improving Outcomes in Chronic Limb-threatening Ischemia: Practical Approaches to Above- and Below-the-knee Interventions
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this targeted 45-minute CME touchpoint, Dr. Anahita Dua, vascular surgeon from Massachusetts General Hospital, and Dr. Mitchell Weinberg from Staten Island University Hospital and Zucker School of Medicine at Hofstra/Northwell, discuss the latest updates in approaches to above-the-knee and below-the-knee interventions for chronic limb-threatening ischemia (CLTI). The faculty will also address assessment of risk severity to recommend the best treatment option. Proper follow-up care for those who require interventions will also be addressed. The touchpoint features images, easy-to-read charts and graphs, and their expert perspectives on above- and below-the-knee interventions to ensure the best clinical outcomes in CLTI..
Featured topic areas include:
• Risk assessment of CLTI
• Above-the-knee interventions
• Challenges of below-the-knee PAD
• Latest clinical trial and safety data
• Case-based applications for practice
This activity is intended for interventional cardiologists, interventional radiologists, vascular surgeons, and other healthcare clinicians interested in treating patients with venous disease.
The burden of chronic limb-threatening ischemia (CLTI) is paramount and has a high incidence of mortality. Properly identifying candidates for endovascular intervention is important along with an understanding of available above-the-knee and below-the-knee interventions. In addition, clinicians need to know safety considerations and proper follow-up care for those who require interventions.
Upon completion of this activity, participants will be able to:
• Discuss the goals of treating CLTI
• Interpret data from clinical trials of drug-coated balloons and other interventions for above-the-knee lesions
• Outline current challenges and emerging approaches for below-the-knee interventions
• Discuss the goals of treating CLTI
• Interpret data from clinical trials of drug-coated balloons and other interventions for above-the-knee lesions
• Outline current challenges and emerging approaches for below-the-knee interventions
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Boston Scientific Corporation.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
5. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
• Background
• Assessing Risks and Identifying Candidates for Endovascular Intervention
• Above-the-knee Interventions
• Challenges of Below-the-knee PAD
• Follow-up care
• Assessing Risks and Identifying Candidates for Endovascular Intervention
• Above-the-knee Interventions
• Challenges of Below-the-knee PAD
• Follow-up care
Anahita Dua, MD, MBA, MSc
Vascular Surgeon
Director MGH Vascular Lab
Co-Director of the MGH Vascular Lab
Associate Director of the MGH Wound Care Center
Massachusetts General Hospital
Boston, MA
Vascular Surgeon
Director MGH Vascular Lab
Co-Director of the MGH Vascular Lab
Associate Director of the MGH Wound Care Center
Massachusetts General Hospital
Boston, MA
Mitchell Weinberg, MD, MBA
Chair, Department of Cardiology
Staten Island University Hospital
Associate Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Anahita Dua, MD, MBA, MSc
Speaker (Education): MiMedx Group, Inc. and Penumbra, Inc.
Mitchell Weinberg, MD, MBA
Consultant (Occasional): Boston Scientific Corporation, Janssen Pharmaceuticals, Magneto Thrombectomy Solutions, Medtronic, MicroVention, Neptune Medical
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: devices under investigation for above-the-knee and below-the-knee interventions
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
This enduring material initially launched on September 23, 2021. The content was re-reviewed for scientific validity and accuracy on February 16, 2022. Accreditation for this activity will expire on September 23, 2023.
